osimertinib
astrazeneca
['tagrisso', 'nsclc', 'sclc', 'astrazeneca']
astrazeneca's tagrisso fails primary endpoint in small neoadjuvant nsclc study. researchers presented an exploratory analysis at asco that provided clues to why the major pathologic response rate in this phase ii study was lower than expected. 